Versant Venture Management LLC held its stake in shares of Audentes Therapeutics, Inc. (NASDAQ:BOLD) during the second quarter, Holdings Channel reports. The institutional investor owned 1,806,832 shares of the biotechnology company’s stock at the end of the second quarter. Audentes Therapeutics makes up approximately 27.2% of Versant Venture Management LLC’s holdings, making the stock its largest position. Versant Venture Management LLC owned 0.07% of Audentes Therapeutics worth $34,583,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in BOLD. Wells Fargo & Company MN increased its stake in shares of Audentes Therapeutics by 278.5% in the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 5,700 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Audentes Therapeutics during the first quarter valued at $184,000. Rhumbline Advisers purchased a new stake in shares of Audentes Therapeutics during the second quarter valued at $252,000. Bank of New York Mellon Corp increased its stake in shares of Audentes Therapeutics by 36.2% in the first quarter. Bank of New York Mellon Corp now owns 18,843 shares of the biotechnology company’s stock valued at $321,000 after buying an additional 5,009 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Audentes Therapeutics by 22.6% in the first quarter. Bank of America Corp DE now owns 23,399 shares of the biotechnology company’s stock valued at $399,000 after buying an additional 4,310 shares during the period. 57.52% of the stock is owned by institutional investors.

Shares of Audentes Therapeutics, Inc. (NASDAQ:BOLD) opened at 17.50 on Friday. The company’s market cap is $383.06 million. The company’s 50 day moving average is $19.92 and its 200 day moving average is $16.80. Audentes Therapeutics, Inc. has a 12 month low of $13.13 and a 12 month high of $22.82.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.77) by $0.10. On average, equities research analysts predict that Audentes Therapeutics, Inc. will post ($3.46) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Versant Venture Management LLC Continues to Hold Position in Audentes Therapeutics, Inc. (NASDAQ:BOLD)” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/12/versant-venture-management-llc-continues-to-hold-position-in-audentes-therapeutics-inc-nasdaqbold.html.

Several equities research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. ValuEngine raised shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 20th. Wedbush reissued an “ourperform” rating and set a $20.00 price target on shares of Audentes Therapeutics in a research report on Monday, May 15th. Finally, Leerink Swann assumed coverage on shares of Audentes Therapeutics in a research report on Monday, May 1st. They set an “outperform” rating and a $22.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $22.25.

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 2,850 shares of the company’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Louis G. Lange sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $19.78, for a total transaction of $296,700.00. Following the transaction, the director now owns 470,799 shares in the company, valued at approximately $9,312,404.22. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,850 shares of company stock valued at $653,700. 47.30% of the stock is currently owned by company insiders.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics, Inc. (NASDAQ:BOLD).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.